On October 20, 2026, Rapport Therapeutics announced that its oral drug RAP-219 met the primary endpoint in a Phase 2 trial of 253 adults with acute bipolar mania, showing a statistically significant 3.1-point placebo-adjusted improvement on the Young Mania Rating Scale. The asset was well-tolerated with no severe adverse events. Analysts highlighted its acceptable safety while noting the modest effect size. Rapport plans to begin Phase 3 trials in the second half of 2027.
Phase 2 trial efficacy results
- ▪Rapport Therapeutics announced on October 20, 2026, that its Phase 2 trial evaluating RAP-219 in 253 adults with acute bipolar mania met its primary endpoint.
- ▪RAP-219 achieved statistical significance on a pre-specified secondary endpoint measuring overall clinician-assessed mania severity at three weeks.
- ▪In the Phase 2 trial, RAP-219 achieved a 3.1-point placebo-adjusted improvement on the Young Mania Rating Scale at three weeks, with a 15.4-point reduction versus 12.3 for the placebo group.
Analyst reactions to trial data
- ▪William Blair analysts stated that the trial results validate RAP-219's proof-of-concept beyond epilepsy, supporting its multi-blockbuster potential across multiple indications.
- ▪Stifel analysts noted that RAP-219's 3.1-point effect size barely reached statistical significance at p=0.045 and sits at the lower end of the competitive 3-to-4 point range.
Executive perspective
- ▪Rapport Therapeutics Chief Executive Officer Abraham Ceesay stated that trial datasets show RAP-219 delivering on its potential as a pipeline-in-a-product across two multibillion-dollar market opportunities.
- ▪Rapport Therapeutics Chief Executive Officer Abraham Ceesay stated that side effect tolerability is critical in bipolar disorder because treatment discontinuation leads directly to relapse.
RAP-219 mechanism of action
- ▪Rapport Therapeutics reported that TARPγ8 is expressed in the hippocampus but minimally expressed in the hindbrain, reducing side effect risks typically linked to hindbrain drug activity.
- ▪RAP-219 is an oral candidate licensed from Johnson & Johnson that functions as a TARPγ8-selective AMPA receptor negative allosteric modulator.
Future trial plans and timeline
- ▪Rapport Therapeutics expects to initiate Phase 3 trials for RAP-219 in acute bipolar mania in the second half of 2027.
- ▪Two Phase 3 trials for RAP-219 in drug-resistant focal onset seizures were listed in a federal trial registry as of late 2026, following a 78% seizure reduction in Phase 2a.
Market reaction and stock performance
- ▪Shares of Rapport Therapeutics rose over 25% to $35.88 in premarket trading on October 20, 2026, before settling down approximately 2% near market open.
- ▪Rapport Therapeutics stock previously surged more than 180% in September 2025 following positive Phase 2a results for RAP-219 in focal epilepsy.
Story comments
Loading comments…